- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01405131
A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets
October 27, 2018 updated by: Pfizer
Phase 1, Open-label, Randomized, Single-dose, 2-treatment, 2 Period Crossover Bioequivalence Study Comparing Constituted Methylprednisolone Powder For Oral Suspension 4 Mg/ml To Methylprednisolone 32 Mg Tablet Under Fasted Conditions
A study to determine whether a new formulation of methylprednisolone suspension is bioequivalent to methylprednisolone tablets.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy male or female subjects between the ages of 21 and 55 years.
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2 and a total body weight > 45 kg (99 lbs).
Exclusion Criteria:
- Any condition possibly affecting drug absorption (eg, gastrectomy).
- A positive urine drug screen
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: methylprednisolone suspension
|
constituted powder for oral suspension 4 mg/mL single dose at 32 mg
tablets 32 mg single dose
|
Active Comparator: methylprednisolone tablets
|
constituted powder for oral suspension 4 mg/mL single dose at 32 mg
tablets 32 mg single dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax (maximum concentration)
Time Frame: 0, 0.5, 1, 2, 3, 4, 5, 6, 10, 12, 16, 24 hours post dose
|
0, 0.5, 1, 2, 3, 4, 5, 6, 10, 12, 16, 24 hours post dose
|
AUCinf (area under the concentration curve to infinity)
Time Frame: 0, 0.5, 1, 2, 3, 4, 5, 6, 10, 12, 16, 24 hours post dose
|
0, 0.5, 1, 2, 3, 4, 5, 6, 10, 12, 16, 24 hours post dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tmax (time at maximum concentration)
Time Frame: 0, 0.5, 1, 2, 3, 4, 5, 6, 10, 12, 16, 24 hours post dose
|
0, 0.5, 1, 2, 3, 4, 5, 6, 10, 12, 16, 24 hours post dose
|
Half-life
Time Frame: 0, 0.5, 1, 2, 3, 4, 5, 6, 10, 12, 16, 24 hours post dose
|
0, 0.5, 1, 2, 3, 4, 5, 6, 10, 12, 16, 24 hours post dose
|
AUC last (area under the concentration curve to last time point)
Time Frame: 0, 0.5, 1, 2, 3, 4, 5, 6, 10, 12, 16, 24 hours post dose
|
0, 0.5, 1, 2, 3, 4, 5, 6, 10, 12, 16, 24 hours post dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2012
Primary Completion (Anticipated)
February 20, 2012
Study Completion (Anticipated)
February 20, 2012
Study Registration Dates
First Submitted
July 25, 2011
First Submitted That Met QC Criteria
July 27, 2011
First Posted (Estimate)
July 29, 2011
Study Record Updates
Last Update Posted (Actual)
October 30, 2018
Last Update Submitted That Met QC Criteria
October 27, 2018
Last Verified
October 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Neuroprotective Agents
- Protective Agents
- Prednisolone
- Methylprednisolone Acetate
- Methylprednisolone
- Methylprednisolone Hemisuccinate
- Prednisolone acetate
- Prednisolone hemisuccinate
- Prednisolone phosphate
Other Study ID Numbers
- B0121006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Therapeutic Equivalency
-
The Affiliated Hospital of Qingdao UniversityCompleted
-
Orphelia PharmaCompletedTherapeutic EquivalencyFrance
-
PfizerCompletedFood | Therapeutic EquivalencyJapan
-
The Affiliated Hospital of Qingdao UniversityCompleted
-
Cao YuUnknownTherapeutic EquivalencyChina
-
PfizerWithdrawn
-
PfizerCompleted
-
Cao YuRecruiting
-
Mylan Pharmaceuticals IncGenpharm ULCCompletedTherapeutic EquivalencyCanada
-
Mylan Pharmaceuticals IncGenpharm ULCCompletedTherapeutic EquivalencyCanada
Clinical Trials on methylprednisolone
-
Rennes University HospitalUnknownMultiple Sclerosis, Relapsing-RemittingFrance
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Chang Gung Memorial HospitalRecruitingMucocutaneous Lymph Node SyndromeTaiwan
-
Fred LublinPfizer; National Multiple Sclerosis SocietyTerminatedMultiple SclerosisUnited States
-
Universidad Nacional Autonoma de MexicoInstituto Nacional de Neurología y NeurocirugíaEnrolling by invitationMethylprednisolone | Intranasal Administration | Patients With an Active Multiple Sclerosis RelapseMexico
-
LEO PharmaBayerCompleted
-
Assiut UniversityCompleted
-
University of Colorado, DenverUniversity of Pennsylvania; MallinckrodtTerminatedMultiple SclerosisUnited States
-
Fundação de Medicina Tropical Dr. Heitor Vieira...CompletedSARS-CoV Infection | Severe Acute Respiratory Syndrome (SARS) PneumoniaBrazil
-
Peking University People's HospitalBeijing HospitalUnknownImmune Thrombocytopenia